Article Information
History
- August 20, 2021.
Article Versions
- Version 1 (May 26, 2021 - 14:51).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Diego Cantoni1,
- Martin Mayora-Neto1,
- Angalee Nadesalingham2,
- David A. Wells2,3,
- George W. Carnell2,
- Luis Ohlendorf2,
- Matteo Ferarri3,
- Phil Palmer2,
- Andrew C.Y. Chan2,
- Peter Smith2,
- Emma M. Bentley5,
- Sebastian Einhauser4,
- Ralf Wagner4,5,
- Mark Page6,
- Gianmarco Raddi7,
- Helen Baxendale7,§,
- Javier Castillo-Olivares2,§,
- Jonathan Heeney2,3,§,*,
- Nigel Temperton1,§,* and
- on behalf of the HICC Consortium8
- 1Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, Chatham, United Kingdom
- 2Laboratory of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom
- 3DIOSynVax, University of Cambridge, Madingley Road, CB3-0ES, Cambridge
- 4Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany
- 5Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany
- 6Division of Virology, National Institute for Biological Standards and Control, Potters Bar, UK
- 7Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK
- ↵*corresponding authors email: n.temperton{at}kent.ac.uk
↵§ contributed equally
Posted August 20, 2021.
Neutralisation hierarchy of SARS-CoV-2 Variants of Concern using standardised, quantitative neutralisation assays reveals a correlation with disease severity; towards deciphering protective antibody thresholds
